Zerion is a pharmaceutical development company aspiring to transform the pharmaceutical landscape with a new formulation technology, Dispersome®, that enables poorly soluble drugs to reach their true therapeutic potential.
The company was established in 2019 as a spinout from the University of Copenhagen based on a decade of research. Zerion is focused on improving existing drug products by building an internal pipeline while partnering with established pharmaceutical companies to solve their most challenging drug solubility problems.
We are on a mission to close a gap between discovery and development of novel drugs
We are dedicated to develop pharmaceutical products and technologies that improve lives and deliver exceptional value to our customers and shareholders
Ole has more than 25 years of executive experience in the pharma and biotech industry. He has prepared and negotiated numerous licensing and collaboration deals at all levels and is the co-founder of five companies in the life science/MedTech field. In 2016 he co-founded and led the MedTech company Cura Nordic until a successful exit in 2018 by way of an asset deal to Karo Pharma AB in Sweden. In 2002, he founded the consultancy firm Wiborg APS which has until today provided high-level scientific and commercial advice to almost 100 clients on 3 continents. Ole has held key management positions as CBO in Larix A/S (DK), Enzymatica AB (SWE), and Prophylix Pharma AS (NO). He worked with TopoTarget A/S as COO and has held various management positions in Nycomed Pharma A/S. Ole holds an M.Sc. in Chemical Engineering from the Technical University (DK) and a B.Econ. in International Trade from Copenhagen Business School (DK).
Korbinian has a strong track record in pharmaceutical formulation and drug delivery with more than 10 years of experience in solid formulation and dosage form development, including pre-formulation, formulation, processing, and manufacturing together with the relevant solid-state characterization and quality control. This includes in particular the development of new enabling formulation strategies for poorly soluble drugs using amorphous drug delivery systems. Korbinian received his PhD in pharmaceutical sciences in 2013 from the University of Otago, New Zealand. He has authored more than 100 peer-reviewed papers and patents.
Jakob is an experienced executive with more than 20 years of experience as a chief financial officer in the biotech industry and 9 years in investment banking. He has been responsible for the financial management in several biotech companies including Galecto Biotech, Asarina Pharma, Acesion Pharma, and Zealand Pharma, and has overseen several public offerings and M&As. He holds an MBA from INSEAD and an M.Sc. in Economics from the University of Copenhagen, Denmark.
Wei has a strong pharma track record with more than 20 years of experience working with pharmaceutical development at some of the leading players within drug delivery and formulation development, including Lonza, Catalent, and Glide Pharma. He has been actively involved in the development and market approval of more than 15 pharmaceutical products, contributing in all stages of pharmaceutical development as well as business development and technical support. Most recently Wei was Director of Formulation at Lonza, with responsibilities in formulation, process development, and clinical trials material manufacture for oral drug products. Prior to that, he held positions as Head of Formulation Development at Norbrook Laboratories and Glide Pharma, both in the UK. He holds a PhD from the University of Leeds and an engineering degree in food sciences from Shanghai Ocean University, China.
Mónica is a pharma regulatory expert with more than 15 years of experience within the multinational pharmaceutical industry, where she has held a number of regulatory positions of increasing responsibility. Most recently, she was Head of Regulatory Affairs for solid dosage forms Chemo Group (Insud Pharma). Prior to that, Mónica worked in regulatory affairs and research and development quality assurance positions in Teva and Wyeth. She holds a Bachelor in Biology and Biotechnology from Complutense University in Madrid, Spain.
Torsten is an experienced life science venture capital investor and has been a partner and director at Rosetta Capital since 2002. Dr. Goesch is also the founder and former managing director of TRG invest, a Munich-based consultancy serving companies in the life science sector. Prior to his role at Rosetta capital, he was the general manager of Biogen in Europe from 1997 to 1999, and before this, he was the commercial head of Merck KGAA's generic drug business, Merck Generics. He brings a wealth of experience to the role, having served on the board of many notable biopharmaceutical companies including Enobia Ltd, Cytochroma Ltd, and the Danish company Forward Pharma. Dr. Goesch is a physician by training and holds an MD and PhD degree from Heinrich Heine University Dusseldorf. Further, he has a Master of Management from the J.L. Kellogg Graduate School of Management at Northwestern University.
Dr. Dorte Arnbjerg (born 1961), is educated as a dentist and holds a Ph.D. degree from the University of Aarhus, and a Master’s degree in Public Health from Johns Hopkins University. Dr. Arnbjerg is an experienced leader & drug developer and joins ZERION’s board with more than 20 years of experience from the pharmaceutical industry. Dr. Arnbjerg has a strong background in international drug development within CMC & clinical development of early and late-stage development programs including successful regulatory drug approvals. Dorte has R&D leadership experience from biotech- & small to large-sized pharmaceutical companies. She is Senior Vice President at H. Lundbeck A/S.
Lars is an experienced life sciences and pharmaceutical executive with a strong clinical and scientific background. He has 20 years of R&D experience from the pharmaceutical industry including CROs providing strategic and operational leadership in drug development programs and 20 years of management experience in pharmaceutical companies. He is currently the Chief Medical Officer in Pharmacosmos A/S, a Danish pharmaceutical company specialized in the manufacturing and development of compounds for treating iron deficiency with or without anemia. He has further served on the board of small to medium-sized pharmaceutical companies providing strategic and operational insights. Lars is a physician by training and holds a Medical degree from the University of Copenhagen and a PhD and DMSc in CNS related pharmacology from the University of Copenhagen.
Jorrit is an experienced scientist with +5 years of experience from the pharmaceutical industry within oral formulation and manufacturing technologies in preclinical R&D. Strong in execution and innovation in formulation research and development as evident from numerous peer-reviewed articles and patents. Jorrit received his PhD in pharmaceutical sciences in 2015 from the University of Copenhagen, Denmark.